Pengaruh kadar low density lipoprotein cholesterol (LDL-C) terhadap derajat keparahan penyakit Parkinson

https://doi.org/10.22146/bns.v18i3.55023

Nita Nathania Agustin(1*), Subagya Subagya(2), Abdul Gofir(3)

(1) KSM Penyakit Saraf, RS Hermina Pasteur, Bandung
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(3) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Penyakit Parkinson (PP) adalah gangguan neurodegeneratif progresif yang berkaitan dengan usia. Beberapa penelitian terbaru menunjukkan bahwa metabolisme lipid dan kolesterol berperan dalam patogenesis penyakit Parkinson. Diduga peningkatan kadar LDL-C dalam darah dapat memperbaiki kondisi klinis gejala Parkinson. Penelitian ini bertujuan untuk mengetahui pengaruh kadar LDL-C dalam darah terhadap derajat keparahan penyakit Parkinson berdasarkan skala Hoehn & Yahr. Desain penelitian ini menggunakan metode cross sectional pada pasien dengan penyakit Parkinson yang kontrol di Poliklinik Saraf RSUP Dr. Sardjito Yogyakarta, RSUD Tjitrowardoyo Purworejo, RSPAU Hardjo Lukito dan RSUP Soeradji Tirtonegoro Klaten. Empat puluh subjek yang masuk ke dalam kriteria inklusi dilakukan penilaian terhadap skala Hoehn & Yahr (stadium I-V) dan pemeriksaan kadar LDL-C. Semua data dianalisis statistik secara komputerisasi. Jumlah subjek dengan stadium I sebanyak 7 (17,5%) subjek, stadium II sebanyak 18 (45%) subjek, stadium III sebanyak 14 (35%) subjek, stadium IV terdapat 1 (2,5%) subjek dan tidak ada subjek stadium V. Rerata kadar LDL-C adalah 109,55±30,31 mg/dL. Hasil analisis multivariat didapatkan pengaruh kadar LDL-C terhadap skala Hoehn & Yahr tidak signifikan (p =0,153). Penelitian ini tidak mendukung adanya pengaruh kadar LDL-C dalam darah terhadap derajat keparahan penyakit Parkinson berdasarkan skala Hoehn & Yahr.


Keywords


kadar LDL-C, derajat keparahan; penyakit Parkinson; Hoehn & Yahr

Full Text:

PDF


References

1. Elbaz A, Bower JH, Maraganore DM, Mcdonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55:25–31.

2. Tanner C. Is the cause of Parkinson’s disease environmental or hereditary? evidence from twin studiesitle. Adv Neurol. 2003;91:133–142.

3. Speelman A, Van De Warrenburg B, Van Nimwegen M, Petzinger G, Munneke M, Bloem B. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol. 2011;7(9):528–534.

4. PERDOSSI. Modul Gangguan Gerak Penyakit Parkinson. Jakarta: Kolegium Neurologi Indonesia; 2008.

5. Reiss AB, Siller KA, Rahman MM, Chan ESL, Ghiso J, De Leon MJ. Cholesterol in neurologic disorders of the elderly: Stroke and Alzheimer’s disease. Neurobiol Aging. 2004;25(8):977–989.

6. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: Prospective results from Honolulu-Asia aging study. Mov Disord. 2008;23(7):1013–1018.

7. Sterling NW, Lichtenstein M, Lee E, Lewis MM, Eslinger PJ, Du G, et al. Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease. Aging Dis. 2016;7(4):1–9.

8. Dahlan MS. Statistik Untuk kedokteran dan Kesehatan: Deskriptif, Bivariat dan Multivariat. Jakarta: Epidemiologi Indonesia; 2014.

9. Benarroch EE. Brain cholesterol metabolism and neurologic disease. Neurology. 2008;71:1368–1371.

10. Harrison DG, Gongora MC. Oxidative Stress a nd Hyp er tension. Med Clin NA. 2009;93(3):621–635. Available from: http://dx.doi.org/10.1016/j.mcna.2009.02.015

11. Behl C. Oestrogen As A Neuroprotective Hormone. Neuroscience. 2002;3:433–442.

12. Dluzen D, McDermott J. Gender differences in neurotoxicity of the nigrostriatal dopaminrgic system: implications for Parkinson’s disease. J gender-specific Med. 1999;3(6):36–42.

13. Sjahrir H, Nasution D, Gofir A. Parkinson’s Disease & Other Movement Disorder. Yogyakarta: Pustaka Cendikia Press; 2007.

14. Hou GJ, Lai CE. Correlations of Serum Uric Acid Level with Parkinson’s Disease Symptom Severity. Park Dis Res Educ Clin Cent (PADR.ECC). 2011.

15. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, et al. Progressive dopaminrgic alterations and mitochonDr.ial abnormalities in LRRK2 G2019S knock in mice. Neurobiol Dis. 2015;78:172–195.

16. Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders: therapeutic implications. Pharmacol Ther. 2014;144(1):50–59.

17. Ahmad B. Management of Late Parkinson’s Disease. In: Parkinson’s Disease and Other Movement Disorder. Edisi Pertama. Yogyakarta: Pustaka Cendikia Press; 2007: 32–33.



DOI: https://doi.org/10.22146/bns.v18i3.55023

Article Metrics

Abstract views : 1143 | views : 2090

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Berkala NeuroSains

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.